^
No biomarker
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
nivolumab
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
methotrexate
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cetuximab
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
afatinib
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
No biomarker
Oral Cancer
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
GDF15 overexpression
Oral Cancer
TPF
Sensitive: C3 – Early Trials
POU5F1 overexpression + NANOG overexpression
Oral Cancer
cisplatin
Resistant: C3 – Early Trials
miR-1290-L
Oral Cancer
5-fluorouracil
Sensitive: C3 – Early Trials
KRAS mutation
Oral Cancer
cetuximab
Resistant: C3 – Early Trials
PD-L1 overexpression
Oral Cancer
nivolumab + MGCD516
Sensitive: C3 – Early Trials
CHEK2 mutation
Tongue Carcinoma
ABT-888 + M6620
Sensitive: C4 – Case Studies
FGFR2 P253R
Tongue Carcinoma
cetuximab
Sensitive: C4 – Case Studies
FGFR2 P253R
Tongue Carcinoma
pazopanib
Sensitive: C4 – Case Studies
PD-L1 overexpression
Oral Cancer
nivolumab + nimotuzumab
Sensitive: C4 – Case Studies
CMTM6 overexpression
Oral Cancer
cisplatin
Resistant: D – Preclinical
EGF expression
Tongue Carcinoma
cetuximab
Resistant: D – Preclinical
PIK3CA Q546R
Oral Cancer
palbociclib
Resistant: D – Preclinical
PIK3CA H1047L
Oral Cancer
palbociclib
Resistant: D – Preclinical
miR-155 overexpression
Oral Cancer
cisplatin
Resistant: D – Preclinical
FOXO3 underexpression
Oral Cancer
cisplatin
Resistant: D – Preclinical